Azeliragon

Generic Name: Azeliragon

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₃₈ClN_₃O_₂

CAS Number: 603148-36-3

Unique Ingredient Identifier: LPU25F15UQ

Background: Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.

Clinical Trials

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Early Phase 1

Not yet recruiting

Conditions: Glioblastoma

Interventions: Drug: Azeliragon
Drug: Temozolomide
Radiation: Radiation therapy
Procedure: Surgery or LITT

First Posted Date: 2025-02-18

Last Posted Date: 2025-02-18

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 12

Registration Number: NCT06831526

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Concurrent Azeliragon With Craniospinal Irradiation

Phase 1

Recruiting

Conditions: Solid Tumor
High-grade Glioma
Leptomeningeal Metastasis

Interventions: Drug: Azeliragon
Procedure: CSI

First Posted Date: 2024-12-09

Last Posted Date: 2025-03-25

Lead Sponsor: NYU Langone Health

Target Recruit Count: 32

Registration Number: NCT06724926

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Azeliragon in MGMT Unmethylated Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Drug: Azeliragon

First Posted Date: 2023-08-14

Last Posted Date: 2024-08-20

Lead Sponsor: Cantex Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT05986851

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Miami Cancer Institute - Baptist Health, Miami, Florida, United States
🇺🇸
The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

and more 5 locations

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Phase 2

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Azeliragon

First Posted Date: 2023-04-18

Last Posted Date: 2025-03-03

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 144

Registration Number: NCT05815485

Locations: 🇺🇸
Rush University, Chicago, Illinois, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Phase 1

Recruiting

Conditions: Cancer
Metastasis
Metastatic Cancer
Brain Metastases
Brain Metastases, Adult

Interventions: Drug: Azeliragon
Radiation: Stereotactic radiosurgery
Drug: Corticosteroid

First Posted Date: 2023-03-29

Last Posted Date: 2024-10-01

Lead Sponsor: Baptist Health South Florida

Target Recruit Count: 46

Registration Number: NCT05789589

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma

Phase 1

Not yet recruiting

Conditions: Glioblastoma
Malignant Glioma

Interventions: Procedure: Biospecimen Collection
Drug: Azeliragon
Procedure: Computed Tomography
Drug: Dexamethasone
Procedure: Magnetic Resonance Imaging of the Brain with and without Contrast

First Posted Date: 2023-03-17

Last Posted Date: 2024-04-25

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 21

Registration Number: NCT05773664

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Azeliragon

First Posted Date: 2023-03-13

Last Posted Date: 2024-06-14

Lead Sponsor: Cantex Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT05766748

Locations: 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Prisma Health - Upstate, Greenville, South Carolina, United States
🇺🇸
Williamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States

and more 3 locations

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Phase 1

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: Azeliragon 5 mg
Drug: Azeliragon 10 mg
Drug: Azeliragon 20 mg

First Posted Date: 2022-12-02

Last Posted Date: 2024-11-18

Lead Sponsor: Cantex Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT05635734

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain

and more 1 locations

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Phase 1

Recruiting

Conditions: Cancer Related Cognitive Decline
Non-metastatic Breast Cancer

Interventions: Drug: TTP488
Drug: ddAC/ddT
Drug: TC
Drug: TCHP
Drug: Chemotherapy regimen that includes ddAC

First Posted Date: 2022-02-25

Last Posted Date: 2024-12-24

Lead Sponsor: Georgetown University

Target Recruit Count: 48

Registration Number: NCT05256745

Locations: 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Phase 2

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Azeliragon

First Posted Date: 2019-06-10

Last Posted Date: 2022-01-21

Lead Sponsor: vTv Therapeutics

Target Recruit Count: 43

Registration Number: NCT03980730

Locations: 🇺🇸
NeuroStudies.net LLC, Decatur, Georgia, United States
🇨🇦
Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada
🇺🇸
Tucson Neuroscience Research, Tucson, Arizona, United States

and more 28 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy